TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3524789
Drug: Chemotherapy (6-mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (6-mercaptopurine 70 mg/m2 days 1-14, methotrexate 15 mg/m2 twice weekly days 15-28, reinduction with daunorubicin 35 mg/m2 and vincristine 1 mg/m2 day 29)
Study: 3524789
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus stanozolol (0.15 mg/kg/day)
Study: 3524789
Drug: 6-thioguanine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine (70 mg/m2 orally on 4 consecutive days) and cytosine arabinoside (80 mg/m2 subcutaneously day 5 every week)
Study: 3524789
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus irradiated blast cells treated with neuraminidase
Study: 31865906
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MBSR and structured exercise
Study: 25970439
Drug: Calcium-rich dairy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-rich dairy based meal (1352 ± 53 mg calcium)
Study: 25970439
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (46 ± 7 mg calcium)
Study: 23123039
Drug: Bupivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5% at 2 cc/h)
Study: 23123039
Drug: Placebo (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5% saline at 2 cc/h)
Study: 19002073
Drug: Depth Jump
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depth Jump (DJ) training for 6 weeks, twice weekly
Study: 19002073
Drug: Countermovement Jump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Countermovement Jump (CMJ) training for 6 weeks, twice weekly
Study: 16481803
Drug: Methylprednisolone 3
Normalized name: methylprednisolone 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 3 mg.kg‐1 (group 1)
Study: 16481803
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg‐1 (group 3)
Study: 16481803
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline physiologic 5 mL (group 2)
Study: 3519093
Drug: Antacid plus
Normalized name: Antacid Plus
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid plus oxethazaine (8 ml doses as needed for 4 weeks)
Study: 3519093
Drug: Antacid alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid alone (8 ml doses as needed for 4 weeks)
Study: 11563588
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan with autologous stem cell transplantation
Study: 26244520
Drug: Tamsulosin 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 400 µg
Study: 26244520
Drug: Nifedipine 30 mg
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 30 mg
Study: 26244520
Drug: Tamsulosin 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 400 µg and Nifedipine 30 mg
Study: 17824846
Drug: CPAP (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP (continuous positive airway pressure) treatment; duration: 1 month; n=12
Study: 16837619
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine per day for 3 months (Group S2)
Study: 16837619
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine per day for 3 months (Group S22)
Study: 16837619
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine per day (Group S212)
Study: 16837619
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg L-selenomethionine per day (Group S21)
Study: 16837619
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine per day (Group S2)
Study: 16837619
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg L-selenomethionine per day (Group S222)
Study: 11482709
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 10 mcg/kg/min
Study: 8097082
Drug: Zalcitabine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine (2.25 mg/d)
Study: 8097082
Drug: Zidovudine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (500 to 1200 mg/d)
Study: 3709638
Drug: cadralazine 15
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cadralazine 15 mg once daily
Study: 8562470
Drug: chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorthalidone 25 mg once daily
Study: 31699944
Drug: ARV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV therapy using fixed-dose combination (tenofovir, lamivudine, efavirenz)
Study: 28124288
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (I-CBT)
Study: 26613606
Drug: Netupitant/palonosetron 300/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netupitant/palonosetron 300/0.5 mg
Study: 26613606
Drug: Palonosetron 0.5
Normalized name: palonosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.5 mg
Study: 23799210
Drug: 4-liter split-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-liter split-dose polyethylene glycol (PEG)
Study: 15350182
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Study: 8591079
Drug: FAM2 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM2 chemotherapy
Study: 8591079
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FAM2 chemotherapy)
Study: 2121487
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents (streptokinase, t‐PA, APSAC)
Study: 25995276
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs) delivered biweekly to homes
Study: 21046070
Drug: maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance treatment (initial optimal therapeutic doses continued throughout the study)
Study: 21046070
Drug: dose-reduction group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose-reduction group (initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction)
Study: 19496901
Drug: Thienopyridine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thienopyridine administration (500 mg ticlopidine or 300 mg clopidogrel)
Study: 17380456
Drug: Postoperative intra-iliac
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intra-iliac and hepatic arterial infusion chemotherapy (group I)
Study: 17380456
Drug: Routine vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vein chemotherapy (group II)
Study: 15499696
Drug: Gefitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib monotherapy (250 mg/day and 500 mg/day)
Study: 23855591
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy program
Study: 9596249
Drug: Acetazolamide 1000
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 1000 mg i.v.
Study: 9596249
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg i.v.
Study: 31753736
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS-ER) and topiramate
Study: 18631255
Drug: Once-daily fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed-dose combination tablet of abacavir and lamivudine (ABC/3TC FDC, Kivexa)
Study: 18631255
Drug: Twice-daily abacavir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily abacavir and lamivudine (ABC and 3TC)
Study: 15536660
Drug: Control (non-medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-medicated cream)
Study: 7677801
Drug: intensive-course 5FU
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive-course 5FU plus low-dose leucovorin (5FU 425 mg/m2 plus leucovorin 20 mg/m2 IV push daily for 5 days, courses repeated at 4- to 5-week intervals)
Study: 7677801
Drug: weekly 5FU
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly 5FU plus high-dose leucovorin (5FU 600 mg/m2 IV push plus leucovorin 500 mg/m2 as a 2-hour infusion weekly for 6 weeks, courses repeated every 8 weeks)
Study: 7677801
Drug: intensive-course 5FU
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive-course 5FU plus low-dose leucovorin
Study: 7677801
Drug: weekly 5FU
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly 5FU plus high-dose leucovorin
Study: 2801549
Drug: beta 1‐adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 1‐adrenergic blockade with optimal dose metoprolol
Study: 342620
Drug: 200 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 CCA units of vaccine
Study: 342620
Drug: 800 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 CCA units of vaccine
Study: 342624
Drug: Subvirion vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion vaccines
Study: 342624
Drug: Whole‐virus vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐virus vaccines
Study: 30949708
Drug: Lefamulin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefamulin (intravenous and oral administration)
Study: 26710008
Drug: Submuscular breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submuscular breast augmentation
Study: 19537523
Drug: Rilmenidine dihydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine dihydrogen phosphate (1.544 mg, equivalent to 1 mg rilmenidine)
Study: 19537523
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (1.544 mg rilmenidine dihydrogen phosphate)
Study: 16403735
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g AAs/kg within the first 24 h
Study: 16403735
Drug: 12 mL
Normalized name: syringe, disposable, 12 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mL MEF x kg(‐1) x d(‐1) within the first 72 h
Study: 15569795
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 microg/kg, single dose)
Study: 15569795
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/day for 21 days)
Study: 17440049
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to beta2-glycoprotein I (abeta2GPI)
Study: 17440049
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to prothrombin (aPT)
Study: 17440049
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to annexin AV (aAnAV)
Study: 17440049
Drug: IgM antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibodies to protein S
Study: 17440049
Drug: LA-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-positive patients with abeta2GPI antibodies
Study: 17440049
Drug: LA-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-positive patients with aPT antibodies
Study: 17440049
Drug: LA-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-positive patients with IgG abeta2GPI and aAnAV antibodies
Study: 7532060
Drug: Intensive, short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive, short-term consolidation (IC) using 1 cycle of intermediate-dose Ara C plus AMSA and 1 cycle of HD-AraC/AMSA
Study: 7532060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (refusals) who received no further treatment after early consolidation
Study: 2122506
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg.kg‐1)
Study: 342247
Drug: Piracetam (4,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4,800 mg daily)
Study: 30813256
Drug: Tomato pomace
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato pomace extract (1 g)
Study: 30813256
Drug: Tomato pomace
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato pomace extract (2.5 g)
Study: 25214979
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized lidocaine inhalation in addition to routine treatment (groups A2 and B1)
Study: 25214979
Drug: Nebulized normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized normal saline apart from routine treatment (groups A1 and B2)
Study: 8985267
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ligation + sclerotherapy)
Study: 2872279
Drug: Alfentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil with neuromuscular blocking agents
Study: 2872279
Drug: Alfentanil without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil without neuromuscular blocking agents
Study: 29795315
Drug: Anticonvulsants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsants with sedation-analgesia (SA)
Study: 29795315
Drug: Anticonvulsants without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticonvulsants without sedation-analgesia (SA)
Study: 29795315
Drug: No exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exposure to SA or anticonvulsants
Study: 19923089
Drug: TACE combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE combined with percutaneous lipiodol and anti-cancer agent injection into the tumor (Group B)
Study: 17600466
Drug: Rituximab +
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab + chemotherapy (CEOP)
Study: 17600466
Drug: Chemotherapy (CEOP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CEOP)
Study: 11429357
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric ropivacaine (18 mg)
Study: 11429357
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine (12 mg)
Study: 9678820
Drug: Mebeverine (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine (135 mg t.d.s.)
Study: 8036831
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (doses ranging from 2.3 to 9.0 x 10(8) CFU, given on days 0, 3, 14, and 17)
Study: 7887022
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine
Study: 6407504
Drug: Fluvoxamine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (mean dose 101 mg/day)
Study: 6407504
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean dose 127 mg/day)
Study: 24839916
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day ferrous fumarate plus 1mg/day folic acid (FFFA group)
Study: 24839916
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day ferrous fumarate alone (FF group)
Study: 24839916
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day ferrous fumarate (both groups)
Study: 21857244
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (group B)
Study: 21857244
Drug: Oral fentanyl
Normalized name: fentanyl Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fentanyl (group C)
Study: 21118495
Drug: ezetimibe +
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe + atorvastatin 40 mg
Study: 26539650
Drug: atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 80 mg
Study: 17658249
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol fumarate 12 microg twice daily for 14 days
Study: 16363240
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg daily
Study: 9456244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of QFIA and traditional cytology
Study: 30959472
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (ice chips) during oxaliplatin infusion
Study: 28650086
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (IV tPA)
Study: 25646792
Drug: Infacort (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infacort (oral hydrocortisone granules with taste masking)
Study: 15505499
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (0.6 mg/h/24 hrs for 6 days)
Study: 9672169
Drug: Interferon-alpha 6
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 6 MU tiw for 8 weeks followed by down-titration (3,1 MU tiw)
Study: 8062564
Drug: Propofol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (mean loading dose 0.24 mg/kg; mean maintenance dose 0.76 mg/kg/hr)
Study: 8062564
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean loading dose 0.012 mg/kg; mean maintenance dose 0.018 mg/kg/hr)
Study: 9186825
Drug: Interferon-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin combination therapy (dosage as for monotherapy) for 6 months
Study: 9186825
Drug: Interferon monotherapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon monotherapy (3 MU 3x/week) for 6 months
Study: 9186825
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy (1000-1200 mg/day) for 6 months
Study: 20521308
Drug: Tailored cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored cognitive-behavioral therapy (CBT) and exercise training (16 sessions over 10 weeks)
Study: 18668592
Drug: Abetimus (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abetimus (100 mg/week for up to 22 months)
Study: 12897643
Drug: Safinamide 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide 2 mg/kg oral load
Study: 8890308
Drug: Motor unit
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor unit activity during agonist and antagonist functions
Study: 6513433
Drug: Verapamil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (40 mg doses p.o./day continuously)
Study: 6513433
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (61 patients treated without additional verapamil therapy)
Study: 30810500
Drug: Protein (≥30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (≥30 g of high-quality protein/meal)
Study: 22494013
Drug: High stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High stimulation (HS) spinal cord stimulation therapy, controlled with a programmer for a minimum of two hours four times daily.
Study: 22494013
Drug: Low stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low stimulation (LS) spinal cord stimulation therapy, received above the paresthesia threshold for one min once daily.
Study: 20028832
Drug: Stress Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Reduction Treatment (SRT)
Study: 17916545
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily plus lansoprazole 30 mg once daily
Study: 12709721
Drug: CGRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP with L‐NMMA (a nitric oxide‐synthase inhibitor)
Study: 12709721
Drug: CGRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP with indomethacin (a cyclooxygenase inhibitor)
Study: 12709721
Drug: CGRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP with tetraethylammonium chloride (TEAC) (a K(+)(Ca)‐channel blocker)
Study: 12709721
Drug: CGRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP with glyburide (INN, glibenclamide) (a K(+)(ATP)‐channel blocker)
Study: 10604047
Drug: SAM patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM patch (50 micrograms/day estradiol)